The relationship between apolipoprotein E (APOE) ε4 and change in cognition was examined in older men (n = 247; age = 75.0 ± 3.5 years) and women (n = 79; age = 70.8 ± 4.9 years) free of history of stroke. Participants were examined again 4.0 ± 0.5 years later. Exclusion criteria were (1) initial scores on the Mini-Mental State Examination of 23 or less or (2) the presence of the APOE 2/4genotype. Men with ε4showed greater decline in some measures of executive function and verbal memory compared to those without ε4; women with ε4showed greater decline in Trail Making test performance relative to women without the allele. A significant gender × APOEε4interaction was seen for change in performance on short delay cued recall. These results suggest that APOEε4is associated with cognitive decline differently in older adult men and women.
Small BJ, Rosnick CB, Fratiglioni L, Backman L.Apolipoprotein E and cognitive performance: a meta analysis. Psychol Aging2004; 19:592-600.
2.
Henderson AS, Easted S, Jorm AF, et al.Apolipoprotein E allele ε4, dementia, and cognitive decline in a population sample. Lancet1995; 346:1387-1390.
3.
Small BJ, Basun H, Backman L.Three-year changes in cognitive performance as a function of apolipoprotein E genotype: evidence from very old adults without dementia. Psychol Aging1998; 13:80-87.
4.
Yaffe K, Cauley J, Sands L, Browner W.Apolipoprotein E phenotype and cognitive decline in a prospective study of elderly community women. Arch Neurol1997; 54:1110-1114.
5.
O’Hara R, Yesavage JA, Kraemer HC, et al.The APOE epsilon 4 allele is associated with decline on delayed recall performance in community-dwelling older adults. J Am Geriatr Soc1998; 46:1493-1498.
6.
Feskens EJ, Havekes LM, Kalmijn S, et al.Apolipoprotein ε4 allele and cognitive decline in elderly men. Br Med J1994; 309:1202-1206.
7.
Kalmijn S, Feskens EJ, Launer LJ, Kromhout D.Cerebrovascular disease, the apolipoprotein ε4 allele, and cognitive decline in a community-based study of elderly men. Stroke1996;27:2230-2235.
8.
Helkala EL, Koivisto K, Hanninen T, et al.Memory functions in human subjects with different apolipoprotein E phenotypes during a 3-year population-based follow-up study. Neurosci Lett1996; 204:177-180.
9.
Kuller LH, Shemanski L, Manolio T, et al.Relationship between APOE, MRI findings, and cognitive function in the Cardiovascular Health Study. Stroke1998; 29:388-398.
10.
Slooter AJ, van Duijn CM, Bots ML, et al.Apolipoprotein E genotype, atherosclerosis, and cognitive decline: the Rotterdam Study. J Neural Transm Suppl1998; 53:17-29.
11.
Carmelli D, Swan GE, Reed T, et al.Midlife cardiovascular risk factors, APOE, and cognitive decline in elderly male twins. Neurology1998; 50:1580-1585.
12.
Jonker C, Schmand B, Lindeboom J, et al.Association between apolipoprotein E epsilon 4 and the rate of cognitive decline in community-dwelling elderly individuals with and without dementia. Arch Neurol1998; 55:1065-1069.
13.
Kang JH, Logroscino G, De Vivo I, et al.Apolipoprotein E, cardiovascular disease and cognitive function in aging women. Neurobiol Aging2005; 26:475-484.
14.
Blair CK, Folsom AR, Knopman DS, et al.Atherosclerosis Risk in Communities (ARIC) Study Investigators. APOE genotype and cognitive decline in a middle-aged cohort. Neurology2005; 64:268-276.
15.
Caselli RJ, Reiman EM, Osborne D, et al.Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele. Neurology2004; 62:1990-1995.
16.
Baxter LC, Caselli RJ, Johnson SC, et al.Apolipoprotein E epsilon 4 affects new learning in cognitively normal individuals at risk for Alzheimer’s disease. Neurobiol Aging2003; 24:947-952.
17.
Ercoli LM, Siddarth P, Dunkin JJ, et al.MMSE items predict cognitive decline in persons with genetic risk for Alzheimer’s disease. J Geriatr Psychiatry Neurol2003; 16:67-73.
18.
Bretsky P, Guralnik JM, Launer L, et al.The role of APOE-epsilon 4 in longitudinal cognitive decline: MacArthur Studies of Successful Aging. Neurology2003; 60:1077-1081.
19.
Wilson RS, Schneider JA, Barnes LL, et al.The apolipoprotein E epsilon 4 allele and decline in different cognitive systems during a 6-year period. Arch Neurol2002; 59:1154-1160.
20.
Mayeux R, Small SA, Tang M, et al.Memory performance in healthy elderly without Alzheimer’s disease: effects of time and apolioprotein E. Neurobiol Aging2001; 22:683-689.
21.
Collie A, Maruff P, Shafiq-Antonacci R, et al.Memory decline in healthy older people: implications for identifying mild cognitive impairment. Neurology2001; 56:1533-1538.
22.
Dik MG, Jonker C, Bouter LM, et al.APOE-epsilon 4 is associated with memory decline in cognitively impaired elderly. Neurology2000; 54:1492-1497.
23.
Hsiung GY, Sadovnick AD, Feldman H.Apolipoprotein E epsilon 4 as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging. CMAJ2004; 171:863-867.
24.
Bunce D, Fratiglioni L, Small BJ, et al.APOE and cognitive decline in preclinical Alzheimer disease and non-demented aging. Neurology2004; 63:816-821.
25.
Yip AG, Brayne C, Easton D, Rubinsztein DC. Medical Research Council Cognitive Function Ageing Study (MRC CFAS). J Med Genet2002; 39:639-643.
26.
Mortenson EL, Høgh P.A gender difference in the association between APOE genotype and age-related cognitive decline. Neurology2001; 57:89-95.
27.
Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res1975; 12:189-198.
28.
Wechsler D. Wechsler Adult Intelligence Scale-Revised. New York: Psychological Corporation, 1981.
29.
Reitan RM. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills1958; 8:271-276.
30.
Stroop Jr.Studies of inference in serial verbal reactions. J Exp Psychol1935; 18:643-662.
31.
Delis DC, Kramer JH, Kaplan E, Ober BA. The California Verbal Learning Test-research edition. New York: Psychological Corporation, 1987.
32.
Austin MA, Ordovas JM, Eckfeldt JH, et al.Guidelines of the National Heart, Lung & Blood Institute Working Group on blood drawing, processing and storage for genetic studies. Am J Epidemiol1996; 144:437-441.
33.
Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res1987; 16:1215-1218.
34.
Hixon JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal. J Lipid Res1990; 31:545-548.
SAS Institute, Inc.SAS/STAT guide version 6. Cary, NC: SAS Institute, 1987.
37.
Talbot CE, Lendon C, Craddock N, et al.Protection against Alzheimer’s disease with APOE e2. Lancet1994; 343:1432-1433.
38.
Kosunen O, Talasniemi S, Lehtovirta M, et al.Relation of coronary atherosclerosis and apolipoprotein E genotypes in Alzheimer patients. Stroke1995; 26:743-748.
39.
Stengard JH, Zerba KE, Pekkanen J, et al.Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men. Circulation1995; 91:265-269.
40.
Wei JY. Disorders of the heart. In: Hazzard WR, Bierman EL, Blass JP, Ettinger WH Jr, Halter JB, eds. Principles of geriatric medicine and gerontology. 3rd ed.New York: McGraw-Hill, 1994: 517-532.
41.
LaRue A, Jarvik LA. Old age and biobehavioral changes. In: Wolman B, ed. Handbook of developmental psychology. Englewood Cliffs, NJ: Prentice Hall, 1982: 791-806.
42.
Frisoni GB, Calabresi L, Geroldi C, et al.Apolipoprotein E epsilon 4 allele in Alzheimer’s disease and vascular dementia. Dementia1994; 5:240-242.
43.
American College of Medical Genetics/American Society of Human Genetics Working Group on APOE and Alzheimer Disease. State of use of apolipoprotein E testing for Alzheimer disease. JAMA1995; 274:1627-1629.
44.
Mayeux R, Ottman R, Maestre G, et al.Synergistic effects of traumatic head injury and apolipoprotein-ε4 in patients with Alzheimer’s disease. Neurology1995; 45:555-557.
45.
van Duijn CM, Havekes LM, van Broeckhoven C, et al.Apolipoprotein E genotype and association between smoking and early onset Alzheimer’s disease. Br Med J1995; 310:627-631.
46.
Yaffe K, Lui L, Grady D, et al.Cognitive decline in women in relation to non-protein-bound oestradiol concentrations. Lancet2000; 356:708-711.
